Publications
- Rituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disorders2009 | First Faculty of Medicine
- Chemotherapy alone may lead to a pcr negative stem cell harvest in transformed lymphoma refractory to rituximab2003 | First Faculty of Medicine
- Anti CD20 Antibody (Rituximab) Therapy Leads to High Molecular Remission Rate with Favourable Outcome in Patients with Non-Hodgkin's Lymphoma2001 | Faculty of Physical Education and Sport
- Comparative Multiplex Polymerase Chain Reaction (PCR) as a Helpful Tool for Monitoring in Patients with LymphomasUndergoing High-dose Therapy (HDT) with Autologous Stem Cell Transplantation (ASCT).2000 | Faculty of Physical Education and Sport
- Comparative Multiplex Polymerase Chain Reaction (PCR) as a Helpful Tool for Monitoring in Patients with LymphomasUndergoing High-dose Therapy (HDT) with Autologous Stem Cell Transplantation (ASCT).2000 | Publication without faculty affiliation
- The Clinical Outcome of Patients with B-cell Lymphoproliferative Disease (B-LPD) Seems to Be Improved by the Success in Induction of Polymerase Chain Reaction (PCR) Negativity Achieved by High Dose Therapy with Autologous Stem Cell TransplantationPublication without faculty affiliation
- PCR Negativity in Patients after Rituximab Therapy for Non-Hodgkin's Lymphoma Is Associated with Better PrognosisPublication without faculty affiliation
- The Clinical Outcome of Patients with B-cell Lymphoproliferative Disease (B-LPD) Seems to Be Improved by the Success in Induction of Polymerase Chain Reaction (PCR) Negativity Achieved by High Dose Therapy with Autologous Stem Cell TransplantPublication without faculty affiliation
- The Outcome of Patients with B-cell Lymphoproliferative Disease (B-LPD) Seems to Be Improved in PCR Negative Patients after High Dose Therapy with Autologous Stem Cell Transplantation or Monoclonal Antibody TherapyPublication without faculty affiliation
- Anti CD20 Antibody (Rituximab) Therapy Leads to High Molecular Remission Rate with Favourable Outcome in Patients with Non-Hodgkin's LymphomaPublication without faculty affiliation
Loading network view...